SG10202001878WA - Methods for treating arenaviridae and coronaviridae virus infections - Google Patents

Methods for treating arenaviridae and coronaviridae virus infections

Info

Publication number
SG10202001878WA
SG10202001878WA SG10202001878WA SG10202001878WA SG10202001878WA SG 10202001878W A SG10202001878W A SG 10202001878WA SG 10202001878W A SG10202001878W A SG 10202001878WA SG 10202001878W A SG10202001878W A SG 10202001878WA SG 10202001878W A SG10202001878W A SG 10202001878WA
Authority
SG
Singapore
Prior art keywords
methods
virus infections
coronaviridae virus
treating arenaviridae
arenaviridae
Prior art date
Application number
SG10202001878WA
Other languages
English (en)
Inventor
Michael O' Neil Hanrahan Clarke
Joy Yang Feng
Robert Jordan
Richard L Mackman
Adrian S Ray
Dustin Siegel
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of SG10202001878WA publication Critical patent/SG10202001878WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG10202001878WA 2015-09-16 2016-09-16 Methods for treating arenaviridae and coronaviridae virus infections SG10202001878WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562219302P 2015-09-16 2015-09-16
US201562239696P 2015-10-09 2015-10-09

Publications (1)

Publication Number Publication Date
SG10202001878WA true SG10202001878WA (en) 2020-04-29

Family

ID=56997582

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202109869X SG10202109869XA (en) 2015-09-16 2016-09-16 Methods for treating arenaviridae and coronaviridae virus infections
SG10202001878WA SG10202001878WA (en) 2015-09-16 2016-09-16 Methods for treating arenaviridae and coronaviridae virus infections

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202109869X SG10202109869XA (en) 2015-09-16 2016-09-16 Methods for treating arenaviridae and coronaviridae virus infections

Country Status (24)

Country Link
US (5) US10251904B2 (pt)
EP (3) EP3785717B1 (pt)
JP (5) JP6742403B2 (pt)
KR (1) KR20180050742A (pt)
CN (5) CN114366745A (pt)
AU (3) AU2016323604B2 (pt)
BR (2) BR112018005048B8 (pt)
CA (1) CA2998189C (pt)
CY (1) CY1125089T1 (pt)
DK (2) DK3349758T3 (pt)
EA (1) EA038141B1 (pt)
ES (2) ES2909419T3 (pt)
HK (3) HK1255732A1 (pt)
HR (2) HRP20220355T1 (pt)
HU (2) HUE058737T2 (pt)
LT (2) LT3785717T (pt)
MA (2) MA42819A (pt)
MX (2) MX2018003161A (pt)
PL (2) PL3785717T3 (pt)
PT (2) PT3349758T (pt)
SG (2) SG10202109869XA (pt)
SI (2) SI3349758T1 (pt)
TW (1) TW201733595A (pt)
WO (1) WO2017049060A1 (pt)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012003126A (es) 2009-09-21 2012-06-19 Gilead Sciences Inc Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos.
US20120027752A1 (en) 2010-07-22 2012-02-02 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
RS62434B1 (sr) 2014-12-26 2021-11-30 Univ Emory Antivirusni n4-hidroksicitidin derivati
BR112018005048B8 (pt) 2015-09-16 2021-03-23 Gilead Sciences Inc uso de um composto antiviral ou sal do mesmo para o tratamento de uma infecção por coronaviridae
US11617753B2 (en) 2016-11-10 2023-04-04 Oyagen, Inc. Methods of treating and inhibiting Ebola virus infection
EP4331677A3 (en) * 2017-03-14 2024-05-29 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
US10836787B2 (en) 2017-05-01 2020-11-17 Gilead Sciences, Inc. Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
AU2018332540B2 (en) * 2017-09-18 2023-10-05 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN111372592A (zh) 2017-12-07 2020-07-03 埃默里大学 N4-羟基胞苷及衍生物和与其相关的抗病毒用途
CN110724174B (zh) * 2019-09-10 2021-02-05 广州六顺生物科技股份有限公司 吡咯并三嗪类化合物、组合物及其应用
CN111265532A (zh) * 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 取代氨基丙酸酯类化合物在治疗2019-nCoV感染中的应用
CA3163424A1 (en) * 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
WO2021158248A1 (en) 2020-02-04 2021-08-12 Oyagen, Inc. Method for treating coronavirus infections
TWI775313B (zh) * 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TW202322824A (zh) 2020-02-18 2023-06-16 美商基利科學股份有限公司 抗病毒化合物
JP7429799B2 (ja) 2020-02-18 2024-02-08 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
CN113292565B (zh) * 2020-02-24 2023-01-31 浙江森科建设有限公司 核苷类化合物及其制备方法和应用
WO2021168930A1 (zh) * 2020-02-25 2021-09-02 顾世海 一种瑞德西韦的片剂及其制备方法
CN111205294B (zh) * 2020-02-27 2021-10-01 江苏阿尔法药业股份有限公司 一种瑞德西韦中间体的制备方法
CN111187269A (zh) * 2020-02-27 2020-05-22 江苏阿尔法药业有限公司 一种瑞德西韦中间体的合成方法
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) * 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
CN111233929B (zh) * 2020-02-28 2023-02-28 成都阿奇生物医药科技有限公司 一种核苷类似物的氘代物及其制备方法和用途
CN113336758B (zh) * 2020-03-03 2022-08-19 北京桦冠医药科技有限公司 化合物7-碘吡咯并[2，1-f][1，2，4]三嗪-4-胺的一种新合成方法
US20230124467A1 (en) * 2020-03-03 2023-04-20 Mios Pharmaceuticals Limited Compounds and methods for treating diseases and/or conditions caused by coronavirus
CN111116656A (zh) * 2020-03-04 2020-05-08 江苏福瑞康泰药业有限公司 一种瑞德西韦的制备方法
CN111269248A (zh) * 2020-03-05 2020-06-12 江苏福瑞康泰药业有限公司 一种核苷氨基磷酸酯类药物母液回收的新方法
CN111233870A (zh) * 2020-03-11 2020-06-05 中国科学技术大学 用于快速制备瑞德西韦药物中间体的方法
JP7554841B2 (ja) 2020-03-12 2024-09-20 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
CN111393478B (zh) * 2020-03-13 2023-05-26 深圳市宝安区新材料研究院 一种瑞德西韦的合成方法
WO2021186439A1 (en) * 2020-03-16 2021-09-23 Bar-Ilan University Molecules that target proteins of coronaviruses and uses thereof as anti-viral "cocktail"
CN113493480A (zh) * 2020-04-03 2021-10-12 南京正大天晴制药有限公司 一种瑞德西韦异构体的制备及其分析方法
US11701372B2 (en) 2020-04-06 2023-07-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
CN116036031A (zh) * 2020-04-07 2023-05-02 齐鲁制药有限公司 一种含有瑞德西韦的药物组合物
WO2021208910A1 (zh) * 2020-04-13 2021-10-21 山东华铂凯盛生物科技有限公司 用于治疗病毒感染的聚合物制剂及制备方法和用途
WO2021211757A1 (en) * 2020-04-14 2021-10-21 Oyagen, Inc. Method for treating arenaviridae infections
CN111848679A (zh) * 2020-04-17 2020-10-30 山东科巢生物制药有限公司 一种利用微通道反应技术合成瑞德西韦的方法
CN113521020B (zh) * 2020-04-18 2023-05-02 齐鲁制药有限公司 一种含有水溶性酸的瑞德西韦固体剂型
CN112778310A (zh) * 2020-04-20 2021-05-11 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN111393243B (zh) * 2020-04-22 2022-12-13 深圳市宝安区新材料研究院 一种磷手性核苷类药物的合成方法及该方法得到的药物
CN111440176B (zh) * 2020-04-28 2022-04-26 江苏大学 金属配合物促进的瑞德西韦中间体的合成方法
CN111494349A (zh) * 2020-04-30 2020-08-07 中国人民解放军空军军医大学 一种瑞德西韦口腔速溶膜及制备方法
CN116549396A (zh) * 2020-05-11 2023-08-08 齐鲁制药有限公司 一种含有瑞德西韦的固体分散体、固体剂型及制备方法
AU2021276914A1 (en) * 2020-05-20 2022-12-01 Lyrus Life Sciences Pvt Ltd Novel composition for the treatment of viral infections
US20230277524A1 (en) 2020-05-22 2023-09-07 Trailhead Biosystems Inc. Combination therapy for treatment of viral infections
US11020349B1 (en) * 2020-07-14 2021-06-01 Jubilant Generics Limited Transmucosal dosage forms of remdesivir
IN202011022634A (pt) 2020-05-29 2020-10-09 Jubilant Generics Limited
EP3915548A1 (en) 2020-05-29 2021-12-01 Jubilant Generics Limited Transmucosal pharmaceutical compositions of antiviral drugs
KR20230018473A (ko) 2020-05-29 2023-02-07 길리애드 사이언시즈, 인코포레이티드 렘데시비르 치료 방법
CN111620909B (zh) * 2020-06-05 2022-12-02 广东中科药物研究有限公司 一种瑞德西韦的前体药物及其制备方法与应用
CA3182179A1 (en) * 2020-06-11 2021-12-16 Fabio E.S. Souza Novel crystalline form of remdesivir
US20210393663A1 (en) * 2020-06-23 2021-12-23 Cai Gu Huang Pharmaceutical formulation containing active metabolites of remdesivir or its analog for inhalation
CN115996928A (zh) 2020-06-24 2023-04-21 吉利德科学公司 1’-氰基核苷类似物及其用途
CN111732618A (zh) * 2020-07-03 2020-10-02 镇江巨杰新材料技术研发中心(有限合伙) 瑞德西韦关键片段的合成方法
WO2022008642A1 (en) 2020-07-08 2022-01-13 Apeiron Biologics Ag Treatment of sars-cov-2 infection with a combination of targets
CN111875638A (zh) * 2020-07-16 2020-11-03 江苏省原子医学研究所 一种瑞德西韦衍生物的制备方法、瑞德西韦衍生物及其应用
CN111961079A (zh) * 2020-07-17 2020-11-20 南京正济医药研究有限公司 一种瑞德西韦有关物质及其制备方法和应用
WO2022020886A1 (en) * 2020-07-27 2022-02-03 Microbio Pty Ltd A detection method for viral replication
CA3188373A1 (en) 2020-08-24 2022-03-03 Scott E. Lazerwith Phospholipid compounds and uses thereof
AU2021331214B2 (en) 2020-08-27 2024-01-04 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
CN112358504A (zh) * 2020-09-28 2021-02-12 南京正济医药研究有限公司 一种瑞德西韦有关物质及其制备方法和用途
CN112194680A (zh) * 2020-09-29 2021-01-08 佛山科学技术学院 核苷酸氨基磷酸酯化合物、其药物组合物及其制备方法和应用
CN112194681A (zh) * 2020-09-29 2021-01-08 佛山科学技术学院 核苷酸长链氨基磷酸酯化合物、其药物组合物及其制备方法和应用
US11612614B2 (en) * 2020-10-20 2023-03-28 Anzalp Pharmasolutions Pvt. Ltd. Isomorphs of Remdesivir and methods for synthesis of same
CN112300236A (zh) * 2020-10-21 2021-02-02 佛山科学技术学院 核苷酸混合氨基磷酸酯化合物、其药物组合物及其应用
CN113754665B (zh) * 2020-12-30 2022-08-19 南方科技大学 一种核苷类化合物的制备方法
US20240317754A1 (en) * 2020-12-30 2024-09-26 Southern University Of Science And Technology Methods and modified nucleosides for treating coronavirus infections
US20220241300A1 (en) * 2021-01-20 2022-08-04 Regents Of The University Of Minnesota Next generation remdesivir antivirals
US11998562B2 (en) 2021-01-25 2024-06-04 University Of South Florida Ophthalmological formulations for the prevention of a coronavirus infection
WO2022166581A1 (zh) * 2021-02-07 2022-08-11 石家庄迪斯凯威医药科技有限公司 一种核苷酸衍生物及其药物组合物和用途
CN113105504B (zh) * 2021-03-30 2024-06-04 澳门科技大学 Remdesivir衍生物、其类似物及其制备方法与应用
EP4323362A1 (en) 2021-04-16 2024-02-21 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
WO2023056936A1 (zh) * 2021-10-07 2023-04-13 南京知和医药科技有限公司 一种核苷酸衍生物及其药物组合物和用途
CN114213366A (zh) * 2022-01-17 2022-03-22 江西师范大学 一种氟代糖内酯合成方法
TW202400185A (zh) 2022-03-02 2024-01-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
WO2023194840A1 (en) 2022-04-05 2023-10-12 Unichem Laboratories Limited Substituted tricyclic compounds and their use in covid-19
US20240051962A1 (en) * 2022-06-29 2024-02-15 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US11655255B2 (en) 2022-10-17 2023-05-23 Sph No.1 Biochemical & Pharmaceutical Co., Ltd. Method for catalytic asymmetric synthesis of phosphorus-stereogenic (P-stereogenic) nucleoside derivative and catalyst used therein
WO2024108130A1 (en) 2022-11-18 2024-05-23 Gilead Sciences, Inc. Methods for treating poxvirus infections
WO2024120464A1 (zh) * 2022-12-09 2024-06-13 深圳市塔吉瑞生物医药有限公司 核苷酸类似物及其组合物及用途
CN117126199A (zh) * 2023-05-17 2023-11-28 江西师范大学 一种氟代瑞德西韦合成方法

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
DK0533833T3 (da) 1990-06-13 1996-04-22 Arnold Glazier Phosphorprolægemidler
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
JPH1017629A (ja) 1996-07-04 1998-01-20 Kayaku Akzo Kk ハードコート用樹脂組成物及びその硬化方法
US6887707B2 (en) 1996-10-28 2005-05-03 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
CN1291994A (zh) 1998-03-03 2001-04-18 诺沃挪第克公司 新的(2e)－5－氨基－5－甲基已－2－烯酸n－甲基－n－((1r)－1－(n－甲基－n－(1r)－1－(甲基氨基甲酰基)－2－苯2基氨基甲酰基－2－(2－萘基)2基酰胺的盐
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6475985B1 (en) 1998-03-27 2002-11-05 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
ES2291043T3 (es) 1998-10-16 2008-02-16 MERCK SHARP & DOHME LIMITED Derivados de pirazolotriazina como ligandos para receptores de gaba.
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
JP2003514766A (ja) 1999-06-03 2003-04-22 アボット・ラボラトリーズ 活性剤としてルイス酸を用いるオリゴヌクレオチド合成
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
WO2001019375A1 (en) 1999-09-15 2001-03-22 Biocryst Pharmaceuticals, Inc. Inhibiting t-cell proliferation
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
CN1427722A (zh) 2000-02-18 2003-07-02 希拉生物化学股份有限公司 用核苷类似物治疗或预防黄病毒感染的方法
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP5230052B2 (ja) 2000-05-26 2013-07-10 イデニクス（ケイマン）リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
AU2001282941C1 (en) 2000-07-21 2016-12-22 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
EP1411954B1 (en) 2000-10-18 2010-12-15 Pharmasset, Inc. Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
EP1539188B1 (en) 2001-01-22 2015-01-07 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
DE10145223A1 (de) 2001-09-13 2003-04-03 Basf Ag Verfahren zur Herstellung von meso-Zeaxanthin
JP2005536440A (ja) 2001-09-28 2005-12-02 イデニクス（ケイマン）リミテツド ４’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物
AT410792B (de) 2001-12-28 2003-07-25 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung
JP2005525358A (ja) 2002-02-28 2005-08-25 ビオタ インコーポレーティッド ヌクレオチド模倣体およびそのプロドラッグ
CA2477795A1 (en) 2002-02-28 2003-09-12 Kandasamy Sakthivel Nucleoside 5'-monophosphate mimics and their prodrugs
US20040138170A1 (en) 2002-03-06 2004-07-15 Montgomery John A. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
GB0210127D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
KR20050006221A (ko) 2002-05-06 2005-01-15 제네랩스 테크놀로지스, 인코포레이티드 Ｃ형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체
WO2003100009A2 (en) 2002-05-23 2003-12-04 Biocryst Pharmaceuticals, Inc. Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
CA2506129C (en) 2002-11-15 2015-02-17 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
NZ544671A (en) 2003-06-26 2009-02-28 Biotron Ltd Antiviral compounds and methods
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2005009418A2 (en) 2003-07-25 2005-02-03 Idenix (Cayman) Limited Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
WO2005021568A2 (en) 2003-08-27 2005-03-10 Biota, Inc. Novel tricyclic nucleosides or nucleotides as therapeutic agents
EP2295422A3 (de) 2004-03-16 2012-01-04 Boehringer Ingelheim International GmbH Glucopyranosylsubstituierte Benzolderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AU2005254057B2 (en) 2004-06-15 2011-02-17 Isis Pharmaceuticals, Inc. C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
WO2006002231A1 (en) 2004-06-22 2006-01-05 Biocryst Pharmaceuticals, Inc. Aza nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
SI3109244T1 (sl) 2004-09-14 2019-06-28 Gilead Pharmasset Llc Priprava 2'fluoro-2'-alkil-substituiranih ali drugih neobvezno substituiranih ribofuranozil pirimidinov in purinov in njihovih derivatov
US20080280842A1 (en) 2004-10-21 2008-11-13 Merck & Co., Inc. Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection
CN101043893A (zh) 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
JP5089395B2 (ja) 2004-10-29 2012-12-05 バイオクライスト ファーマシューティカルズ， インコーポレイテッド 治療用フロピリミジンおよびチエノピリミジン
EP1828216B1 (en) 2004-12-16 2008-09-10 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
AU2006222563A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
JP5107228B2 (ja) 2005-03-29 2012-12-26 バイオクライスト ファーマシューティカルズ， インコーポレイテッド Ｃ型肝炎治療
WO2006116557A1 (en) 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
PL2826770T3 (pl) 2005-06-24 2019-02-28 Biotron Limited Przeciwwirusowe związki acyloguanidynowe
CN101321775B (zh) 2005-10-03 2012-05-23 大学健康网络 用于治疗疟疾的odcase抑制剂
EP1945222B1 (en) 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
BRPI0619120B1 (pt) 2005-12-01 2023-10-10 Basilea Pharmaceutica Ag Processo para a fabricação de derivados de epóxi triazol
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
US8143393B2 (en) 2005-12-02 2012-03-27 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
UA91255C2 (uk) 2005-12-09 2010-07-12 Ф. Хоффманн-Ля Рош Аг Антивірусні нуклеозиди
EP1971331A2 (en) 2005-12-09 2008-09-24 Basilea Pharmaceutica AG 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders
AU2007215114A1 (en) 2006-02-14 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
WO2007097991A2 (en) 2006-02-16 2007-08-30 Pharmasset, Inc. Methods and kits for dosing of antiviral agents
DE102006015378A1 (de) 2006-04-03 2007-10-04 Ludwig-Maximilians-Universität München Verfahren zur Synthese von Organoelementverbindungen
CL2007001427A1 (es) 2006-05-22 2008-05-16 Novartis Ag Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
US7842672B2 (en) 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
WO2008033466A2 (en) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
CA2668623A1 (en) 2006-11-06 2008-05-15 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008079206A1 (en) 2006-12-20 2008-07-03 Merck & Co., Inc. Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
JP2010515680A (ja) 2007-01-05 2010-05-13 メルク・シャープ・エンド・ドーム・コーポレイション Ｒｎａ依存性ｒｎａウイルス感染症の治療用としてのヌクレオシドアリールホスホロアミデート
NZ578556A (en) 2007-01-12 2012-04-27 Biocryst Pharm Inc Antiviral nucleoside analogs
CN101730699A (zh) 2007-03-21 2010-06-09 百时美施贵宝公司 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
ES2393038T3 (es) 2007-05-10 2012-12-18 Biocryst Pharmaceuticals, Inc. Compuestos de tretrahidrofuro[3,4-D]dioxolano para su utlilización en el tratamiento de las infecciones víricas y del cáncer
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
PL2194976T3 (pl) 2007-08-03 2016-06-30 Biotron Ltd Kompozycje antywirusowe przeciwko zapaleniu wątroby typu C zawierające 5-(1-metylopirazol-4-ilo)-2-naftoiloguanidynę i 2'-C-metyloadenozynę lub 2'-C-metylocytydynę
KR101502533B1 (ko) 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
ES2398684T3 (es) 2008-04-23 2013-03-21 Gilead Sciences, Inc. Análogos de carbanucleósido para el tratamiento antiviral
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
WO2010002877A2 (en) * 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
CA2751277C (en) 2009-02-10 2018-10-30 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
EA201190178A1 (ru) 2009-03-20 2012-06-29 Алиос Биофарма, Инк. Замещённые нуклеозидные и нуклеотидные аналоги
AU2010230008B2 (en) 2009-03-24 2015-06-04 Biocryst Pharmaceuticals, Inc. Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1- ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
CN102471327A (zh) 2009-07-21 2012-05-23 吉里德科学公司 黄病毒科病毒的抑制剂
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
EP2480552B1 (en) 2009-09-21 2016-11-09 Gilead Sciences, Inc. 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
MX2012003126A (es) 2009-09-21 2012-06-19 Gilead Sciences Inc Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos.
AU2010338011B2 (en) 2009-12-28 2015-04-02 Development Center For Biotechnology Novel pyrimidine compounds as mTOR and P13K inhibitors
AP3515A (en) 2010-03-31 2016-01-11 Gilead Pharmasset Llc Nucleoside phosphoramidates
UY33310A (es) 2010-03-31 2011-10-31 Pharmasset Inc Sintesis estereoselectiva de activos que contienen fosforo
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
BR112013001267A2 (pt) 2010-07-19 2016-05-17 Gilead Sciences Inc métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro
US20120027752A1 (en) 2010-07-22 2012-02-02 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
PE20131165A1 (es) 2010-09-20 2013-10-14 Gilead Sciences Inc Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
CN103209987B (zh) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
LT2898885T (lt) 2010-10-15 2018-02-26 Biocryst Pharmaceuticals, Inc. Pirolopirimidino dariniai, skirti naudoti virusinių infekcijų gydymui
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
AU2011349844B2 (en) 2010-12-20 2017-06-01 Gilead Sciences, Inc. Combinations for treating HCV
BR112013026219A2 (pt) 2011-04-13 2016-07-26 Gilead Sciences Inc análogos de n-nucleosídeo 1'-substituída pirimidina para tratamento antiviral
KR20130138840A (ko) 2011-04-13 2013-12-19 머크 샤프 앤드 돔 코포레이션 2''-치환된 뉴클레오시드 유도체 및 바이러스성 질환의 치료를 위한 그의 사용 방법
CA2836098C (en) 2011-05-13 2022-06-21 Zoetis Llc Hendra and nipah virus g glycoprotein immunogenic compositions
UA116087C2 (uk) 2011-09-16 2018-02-12 Гіліад Фармассет Елелсі Композиція для лікування вірусу гепатиту c
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US20130143835A1 (en) 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
WO2013084165A1 (en) 2011-12-05 2013-06-13 Medivir Ab Hcv polymerase inhibitors
AU2012358804B2 (en) 2011-12-22 2018-04-19 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
AU2013266393B2 (en) 2012-05-22 2017-09-28 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
ES2671478T3 (es) 2012-08-31 2018-06-06 Novartis Ag Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales
MA37942B1 (fr) 2012-09-10 2020-01-31 Hoffmann La Roche Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
WO2014042433A2 (en) 2012-09-14 2014-03-20 Kainos Medicine, Inc. Compounds and compositions for modulating adenosine a3 receptor activity
JP2016504284A (ja) * 2012-11-16 2016-02-12 バイオクリスト ファーマスーティカルズ，インコーポレイテッドＢｉｏｃｒｙｓｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 抗ウイルス性アザ糖を含有するヌクレオシド
MX2015006248A (es) 2012-11-19 2015-08-14 Merck Sharp & Dohme Derivados de nucleosido 2'-alquinilo sustituido para el tratamiento de enfermedades virales.
SG11201504554UA (en) 2012-12-21 2015-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9283242B2 (en) * 2013-01-22 2016-03-15 Massachusetts Institute Of Technology Uses of dihydro bases
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
CN105377868A (zh) 2013-04-12 2016-03-02 艾其林医药公司 用于治疗hcv的高活性核苷衍生物
US9542154B2 (en) 2013-06-25 2017-01-10 Intel Corporation Fused multiply add operations using bit masks
UA117375C2 (uk) 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
EP3711762A1 (en) 2013-09-11 2020-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) A farnesoid x receptor agonsits foruse and pharmaceutical compositions for the treatment of chronic hepatitis b virus infection
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
SG11201605970QA (en) 2014-01-30 2016-08-30 Hoffmann La Roche Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
DK3114128T3 (en) 2014-03-07 2019-03-25 Hoffmann La Roche New 6-fused heteroaryld dihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
WO2015173164A1 (en) 2014-05-13 2015-11-19 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
US9616076B2 (en) 2014-06-02 2017-04-11 The Board Of Regents Of The University Of Texas Systems Methods for treating viral infections using hydrogen sulfide donors
US9504701B2 (en) 2014-06-02 2016-11-29 The Board Of Regents Of The University Of Texas System Methods for treating viral infections using hydrogen sulfide donors
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
EP3180319B1 (en) 2014-08-14 2018-10-03 F.Hoffmann-La Roche Ag Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
WO2016102438A1 (en) 2014-12-23 2016-06-30 F. Hoffmann-La Roche Ag Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine analogues
CN107108610B (zh) 2014-12-30 2019-06-04 豪夫迈·罗氏有限公司 用于治疗和预防肝炎b病毒感染的新的四氢吡啶并嘧啶和四氢吡啶并吡啶化合物
EP3240913A1 (en) 2014-12-31 2017-11-08 F. Hoffmann-La Roche AG A novel high-throughput method for quantification of hbv cccdna from cell lysate by real-time pcr
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
WO2016120186A1 (en) 2015-01-27 2016-08-04 F. Hoffmann-La Roche Ag Recombinant hbv cccdna, the method to generate thereof and the use thereof
CN107207505B (zh) 2015-02-11 2018-12-14 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的 2-氧代-6,7-二氢苯并[a]喹嗪-3-甲酸衍生物
BR112018005048B8 (pt) * 2015-09-16 2021-03-23 Gilead Sciences Inc uso de um composto antiviral ou sal do mesmo para o tratamento de uma infecção por coronaviridae
WO2017184668A1 (en) 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
CN108299532B (zh) 2016-12-29 2020-12-22 广东东阳光药业有限公司 一种抗病毒核苷类似物前药及其组合物、用途
US10918623B2 (en) 2017-02-08 2021-02-16 Biotron Limited Methods of treating influenza
EP4331677A3 (en) 2017-03-14 2024-05-29 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
US10836787B2 (en) 2017-05-01 2020-11-17 Gilead Sciences, Inc. Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
CN111265532A (zh) 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 取代氨基丙酸酯类化合物在治疗2019-nCoV感染中的应用
CA3163424A1 (en) 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
JP7554841B2 (ja) 2020-03-12 2024-09-20 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
US11701372B2 (en) 2020-04-06 2023-07-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
KR20230018473A (ko) 2020-05-29 2023-02-07 길리애드 사이언시즈, 인코포레이티드 렘데시비르 치료 방법
AU2021331214B2 (en) 2020-08-27 2024-01-04 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Also Published As

Publication number Publication date
HRP20220740T1 (hr) 2022-11-11
TW201733595A (zh) 2017-10-01
CN116617233A (zh) 2023-08-22
CY1125089T1 (el) 2023-06-09
US10695361B2 (en) 2020-06-30
CN108348526A (zh) 2018-07-31
US20230027727A1 (en) 2023-01-26
US11007208B2 (en) 2021-05-18
HUE057928T2 (hu) 2022-06-28
JP2023085459A (ja) 2023-06-20
HRP20220355T1 (hr) 2022-05-13
SG10202109869XA (en) 2021-10-28
CN114366745A (zh) 2022-04-19
PL3785717T3 (pl) 2022-05-02
CA2998189A1 (en) 2017-03-23
HK1255732A1 (zh) 2019-08-23
WO2017049060A1 (en) 2017-03-23
US11382926B2 (en) 2022-07-12
US20210393659A1 (en) 2021-12-23
JP2018531227A (ja) 2018-10-25
SI3785717T1 (sl) 2022-04-29
CA2998189C (en) 2021-08-03
DK3785717T3 (da) 2022-03-21
CN115887465A (zh) 2023-04-04
HUE058737T2 (hu) 2022-09-28
BR122020020217B1 (pt) 2021-08-17
JP6742403B2 (ja) 2020-08-19
EP3349758A1 (en) 2018-07-25
JP2020111587A (ja) 2020-07-27
LT3785717T (lt) 2022-04-11
AU2020233714A1 (en) 2020-10-08
MA42819A (fr) 2018-07-25
JP2021107431A (ja) 2021-07-29
US20190255085A1 (en) 2019-08-22
ES2909419T3 (es) 2022-05-06
PL3349758T3 (pl) 2022-09-12
BR112018005048B8 (pt) 2021-03-23
AU2020233714B2 (en) 2022-11-24
MA52371A (fr) 2021-09-22
EA038141B1 (ru) 2021-07-13
DK3349758T3 (da) 2022-06-13
MX2018003161A (es) 2018-05-17
KR20180050742A (ko) 2018-05-15
ES2918585T3 (es) 2022-07-19
AU2016323604A1 (en) 2018-03-29
US10251904B2 (en) 2019-04-09
EP3785717B1 (en) 2022-01-05
US20170071964A1 (en) 2017-03-16
US20200352967A1 (en) 2020-11-12
SI3349758T1 (sl) 2022-08-31
EP3785717A1 (en) 2021-03-03
PT3349758T (pt) 2022-07-13
AU2016323604B2 (en) 2020-07-09
PT3785717T (pt) 2022-04-14
EP4088718A1 (en) 2022-11-16
JP2024081784A (ja) 2024-06-18
HK1257628A1 (zh) 2019-10-25
MX2021005087A (es) 2022-08-18
LT3349758T (lt) 2022-07-11
EA201890494A1 (ru) 2018-10-31
HK1256872A1 (zh) 2019-10-04
AU2023200990A1 (en) 2023-03-23
BR112018005048B1 (pt) 2021-02-23
CN115844896A (zh) 2023-03-28
JP7254738B2 (ja) 2023-04-10
EP3349758B1 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
HK1257628A1 (zh) 治療沙粒病毒科和冠狀病毒科病毒感染的方法
HK1258795A1 (zh) 絲狀病毒科病毒感染的治療方法
EP3139954A4 (en) Methods and compositions for treating hepatitis b virus infections
IL254596A0 (en) A method for operating a reverse osmosis membrane treatment system and a reverse osmosis membrane treatment system
HK1231402A1 (zh) 治療 型肝炎和 型肝炎病毒感染的方法
IL256972A (en) Methods for detecting and treating low-virulence infections
DK3383804T3 (da) Regnvandsbehandlingsapparat, -fremgangsmåde og -system
SG11201710014QA (en) Affair processing method and device
GB2539474B (en) Glove and treatment method
GB201708778D0 (en) Virus and method
GB201708779D0 (en) Virus and method
SG11201804140PA (en) Acidic-gas treating agent and acidic-gas treating method
GB2586097B (en) Glove and treatment method
TH1501004125A (th) สารประกอบและวิธีการสำหรับการรักษาการติดเชื้อแบคทีเรีย